Articles On Immutep (ASX:IMM)

Title Source Codes Date
Immutep reports new data from phase 2 TACTI-002 trial

Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials. The phase 2 TACTI-002 trial is studying the company's LAG-3 Candidate, eftilagimod...

BiotechDispatch IMM 1 week ago
What’s the outlook for Immutep shares in FY23?

Immutep Ltd (ASX: IMM) shares underperformed in FY22 as markets took a turn for the worse. Most of the previous year’s gains were erased. However, the biotech company has caught a bid in July, as healthcare shares continue to strengthen i...

Motley Fool IMM 3 weeks ago
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Stockhead IMM 3 weeks ago
What’s the outlook for ASX biotech shares in FY23?

ASX biotech shares incurred heavy losses in FY22 as investors piled out of risk assets and moved into higher-quality corners of the market. Here’s a closer look at three noteworthy ASX biotech shares and their outlook for FY23. CSL Ltd...

Motley Fool IMM 1 month ago
Why did the Immutep share price plummet 31% last month?

The Immutep Ltd (ASX: IMM) share price plunged lower in June despite the company announcing seemingly good news to the market. As of the final close of last month, the Immutep share price was 29 cents, 30.95% lower than it was at the end o...

Motley Fool IMM 1 month ago
Here’s how ASX healthcare shares performed in FY22

ASX healthcare shares were a mixed basket this past financial year. After a healthy first half of FY22, the sector took a massive plunge from the restart of trade in January. The S&P/ASX 200 Health Care Index (ASX: XHJ) fell around...

Motley Fool IMM 1 month ago
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Stockhead IMM 1 month ago
Evening Report: 6 July, 2022

ShareCafeEvening Report: 6 July, 2022 by Lauren Evans   Australian shares spent the afternoon in the red as commodity prices plunged on recession fears. The energy sector tumbled 5.8 per cent, with materials down 5 per cent. Real estate was...

ShareCafe IMM 1 month ago
ASX Health Stocks: ResApp gets FDA nod, while Japan grants Immutep a patent

ResApp gets clearance from the US FDA Immutep is granted patent in Japan Paradigm Biopharma to commence Phase 3 trial ResApp Health (ASX:RAP) announced that SleepCheckRx has received 510(k) clearance as a prescription-only Software-as-a-M...

Stockhead IMM 1 month ago
Lunch Report: 6 July, 2022

ShareCafeLunch Report: 6 July, 2022 by Melissa Darmawan   The Australian sharemarket has been choppy this morning, trading as low as 0.5 per cent before rebounding to a gain of 0.2 per cent to then fall again. Information technology shares...

ShareCafe IMM 1 month ago
Immutep (ASX:IMM) granted Japanese patent for IMP761

Immutep (IMM) is granted a Japanese patent for its pre-clinical product candidate, IMP761, valid until 2036 The patent is entitled “Anti-LAG-3 Antibodies” and was granted by the Japanese Patent Office The new patent follows the grant of th...

themarketherald.com.au IMM 1 month ago
Immutep (ASX:IMM) granted Japanese patent for IMP761

06 Jul 2022 - Immutep (ASX:IMM) has been granted a Japanese patent for its IMP761, an immunosuppressive agonist antibody targeting LAG-3 for autoimmune diseases.

FNN IMM 1 month ago
Here’s how ASX 200 healthcare shares performed in June

ASX 200 healthcare shares were defensive in June but finished the month down overall. The benchmark S&P/ASX 200 Health Care Index (ASX: XHJ) was volatile, slipping 3% in June. Nevertheless, there were some names worth mentioning. Let’...

Motley Fool IMM 1 month ago
Own Immutep shares? Here are 3 takeaways from the company’s investor update

Shares of biotech Immutep Ltd (ASX: IMM) have had a hard time this year to date, down 35% since trading resumed in January. At the time of writing, investors are paying 30.5 cents apiece for the Immutep share price. Earlier this month,...

Motley Fool IMM 1 month ago
I think these 2 ETFs are too good to miss in July 2022

Exchange-traded funds (ETFs) can be very useful for investing in shares. ETFs make it to invest passively, get access to different industries or invest in different geographic markets. One of the most popular ETFs is one that gives access...

Motley Fool IMM 1 month ago
What’s driving the Immutep share price in June?

The Immutep Ltd (ASX: IMM) share price has gyrated in recent months, having slumped from a 52-week high of 71 cents back in November to close Friday’s session at 37 cents. Investors pushed the stock to 52-week lows by April this year, wh...

Motley Fool IMM 2 months ago
2022 Has Been Rough for Major Indexes. Here’s Why I’m Not Worried.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. After rallying from t...

Motley Fool IMM 2 months ago
Is The Stock Market Going to Crash Again?

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. With the recent infla...

Motley Fool IMM 2 months ago
ASX shares and inheritances: Survey reveals how Aussies plan to get rich

Men are more likely to invest in ASX shares than women. That’s according to a new YouGov survey commissioned by crypto wealth platform Dacxi. The survey also found that men are almost twice as likely to believe they’ll be rich in their...

Motley Fool IMM 2 months ago
Immutep (ASX:IMM) TACTI-002 data presented at ASCO 2022

ShareCafeImmutep (ASX:IMM) TACTI-002 data presented at ASCO 2022   Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Vice President Strategic Development Christia...

ShareCafe IMM 2 months ago
Australian Broker Call *Extra* Edition – Jun 08, 2022

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

FNArena IMM 2 months ago
Short & Caught: Flight Centre and rate sensitive stocks among ASX most shorted

In Short & Caught, Stockhead recaps the ASX stocks that are the most shorted and have had the greatest increase in short interest right now.   How does shorting work? Shorting works by selling stocks you do not actually own in the hope...

Stockhead IMM 2 months ago
Immutep reports positive overall response rate in lung cancer trial

Immutep (ASX:IMM) has released new data from the phase 2 lung cancer trial evaluating its lead product candidate eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients.

BiotechDispatch IMM 2 months ago
Evening Report: 6 June, 2022

ShareCafeEvening Report: 6 June, 2022 by Lauren Evans   The Aussie sharemarket remained in the red for the afternoon session following a weak lead from Wall Street. The Reserve Bank of Australia is set to meet tomorrow, which means investor...

ShareCafe IMM 2 months ago
Lunch Report: 6 June, 2022

ShareCafeLunch Report: 6 June, 2022 by Melissa Darmawan   The Australian sharemarket has retreated this morning after three weeks of gains ahead of the Reserve Bank of Australia policy meeting tomorrow. Energy is the clear winner while cons...

ShareCafe IMM 2 months ago
ASX Health Stocks: Clarity Pharma gets the go-ahead from US FDA

US FDA approves Clarity Pharma’s IND application Radiopharma-focused biotech, Clarity Pharmaceuticals (ASX: CU6), has announced the approval of its Investigational New Drug (IND) application by the US FDA. The approval was received for Clar...

Stockhead IMM 2 months ago
Stocks of the Hour: Immutep, Liontown Resources & Calidus Resources

06 Jun 2022 - A snapshot of the stocks on the move featuring Immutep (ASX:IMM), Liontown Resources (ASX:LTR) & Calidus Resources (ASX:CAI).

FNN IMM 2 months ago
Immutep (ASX:IMM) shares positive results in phase two efti combination trial

Immutep (IMM) publishes new “favourable” data from its first line non-small cell lung cancer (NSCLC) patients of its Phase II TACTI-002 trial The trial is evaluating eftilagimod alpha (efti) when used with collaboration partner MSD’s anti-...

themarketherald.com.au IMM 2 months ago
ScoPo’s Powerplays: Who stands out in the enterprise imaging sector?

ASX healthcare index finishes another week in the red Enterprise imaging stocks tipped to be a first recovery The goliath battle for fertility company Virtus comes to an end Healthcare and life sciences expert Scott Power – a senior analy...

Stockhead IMM 2 months ago
ASX Small Cap May Winners: Galileo. Galileo. Galileo. And some other stocks

May. Let’s start with US markets. Because May in the US started with the Dow making its biggest gain since 2020, followed within 24 hours by its biggest loss in 2022, perfectly summing up what kind of month May was to become. The US Fed rai...

Stockhead IMM 2 months ago
Why has the Immutep share price rocketed 24% in a month?

The last 30 days have been bright for the Immutep Ltd (ASX: IMM) share price. The biotechnology company’s surge followed two announcements regarding its lead product candidate, efti. At the time of writing, the Immutep share price is 41 ce...

Motley Fool IMM 2 months ago
ASX Health Stocks: Race Oncology blows past dosing stage of Phase 1, targets Phase 2

Race Oncology completed dosing stage of Phase, eyes Phase 2 trial Immutep presents trials data at ASCO 2022 meeting Clarity Pharma presents at the Jefferies Biotech Summit Race Oncology (ASX:RAC) has completed the dose escalation stage of...

Stockhead IMM 2 months ago
Immutep (ASX:IMM) publishes “favourable” interim data from second-phase efti trial

Immutep (IMM) publishes new interim data from Part A of its second-phase TACTI-002 trial showing “favourable” antitumour activity for its eftilagimod alpha (efti) drug. Data from the trial will be presented in an oral presentation on June...

themarketherald.com.au IMM 2 months ago
Market Highlights and 5 ASX Small Caps to Watch on Friday

 ASX to open 1% higher this morning Wall Street surge in a broad based rally overnight April retail sales data to be released today Local shares are poised to open higher this morning following a jump in US stocks overnight. At 8am AEDT,...

Stockhead IMM 2 months ago
Immutep Limited (ASX:IMM) Investor Presentation

ShareCafeImmutep Limited (ASX:IMM) Investor Presentation Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt provides an overview of the company, discussing the LAG-3 immune checkpoint, Immutep’s LAG-3 pipeline, eftilagimod alp...

ShareCafe IMM 2 months ago
ScoPo’s Powerplays: Health stocks strap in for a ‘skittish’ ride

ASX Health stocks endure another topsy-turvy week ending in red Monash IVF makes two key purchases to expand its foothold in fertility sector Actinogen Medical to push ahead with trial into treatment of early Alzheimer’s disease. Healthca...

Stockhead IMM 2 months ago
Immutep appoints leading oncologists to clinical advisory board

Immutep (ASX:IMM) has announced the appointment of four new members to its Clinical Advisory Board.

BiotechDispatch IMM 2 months ago
Sector Watch: Healthcare - M&A fever on the cards?

11 May 2022 - A snapshot of stocks in the healthcare sector, including Antisense Therapeutics (ASX:ANP), Kazia Therapeutics (ASX:KZA), and Immutep (ASX:IMM).

FNN IMM 3 months ago
ScoPo’s Powerplays: Health stocks tumble but half-price sale presents buying opportunities

Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Are you the cuddly type?...

Stockhead IMM 3 months ago
10-baggers? Expert names 2 super-cheap biotech ASX shares

Biotechnology ASX shares have been one of the biggest victims of persistent inflation and rising interest rate fears over the past 6 months.  The S&P/ASX 300 Pharmaceuticals & Biotechnology (ASX: AXPBKD) has lost about 15% over tha...

Motley Fool IMM 3 months ago
Immutep (ASX:IMM) shares positive data from phase 2b AIPAC trial

Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-n...

themarketherald.com.au IMM 3 months ago
Immutep’s (ASX:IMM) interim data selected for presentation

Immutep’s (IMM) new interim data is selected for presentation at the the world’s largest gathering of oncology professionals New interim data from first line non-small cell lung cancer patients of Immutep’s Phase II trial has been selected...

themarketherald.com.au IMM 3 months ago
Check Up: Money managers are still bullish on Healthcare; here’s what they said

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Stockhead IMM 3 months ago
How Immutep Treats Head & Neck Cancer

ShareCafeHow Immutep Treats Head & Neck Cancer   While Immutep boasts development candidates that have been licenced to Novartis AG (SWX: NOVN) in the area of cancer and GlaxoSmithKline plc (GSK; LON: GSK) in the area of autoimmune dis...

ShareCafe IMM 4 months ago
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Stockhead IMM 4 months ago
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Stockhead IMM 4 months ago
Immutep (ASX:IMM) reports ‘encouraging’ trial results in second line metastatic lung cancer cases

Biotechnology company Immutep (IMM) announces new interim data in its treatment of second line metastatic non-small cell lung carcinoma (NSCLC) patients from its Phase 2 TACTI-002 trial Key findings of the trial include a 73.7 per cent of...

themarketherald.com.au IMM 4 months ago
Who got what in the healthcare budget, and which ASX stocks could benefit

The healthcare sector is Australia’s biggest employer, employing 1 in 7 Aussies or roughly two million people. Treasurer Josh Frydenberg announced last night that Australia’s health budget will top $132bn in 2022-23, up from $62bn a decade...

Stockhead IMM 4 months ago
Market Highlights and 5 ASX Small Caps to watch on Wednesday

ASX set to rise as US tech stocks rally Sectors that got a big boost from Fed Budget include road and rail infrastructure ($18bn), defence ($15bn), and cybersecurity ($10bn) 5 ASX small caps to watch today: Immutep, Torque Metals, Elsight,...

Stockhead IMM 4 months ago
ACW, HXL, IMM – ASX biotech stocks that gained over 25% in 52 weeks

Highlights Biotechnology companies research living organisms to develop drugs and other products. Investing in biotechnology stocks require due diligence and caution to make a profit and avoid loss. The S&P/ASX 200 Health Care ind...

Kalkine Media IMM 4 months ago